A Phase III randomized, double-blind, placebo-controlled study of pilocarpine for vaginal dryness: North central cancer treatment group study N04CA

Journal of Supportive Oncology

Volumn 9, Issue 3, 2011, Pages 105-112

  Loprinzi, Charles L ^{a,b,c,d,e,f,g}   Balcueva, Ernie P ^{a,b,c,d,e,f,g}   Liu, Heshan ^{a,b,c,d,e,f,g}   Sloan, Jeff A ^{a,b,c,d,e,f,g}   Kottschade, Lisa A ^{a,b,c,d,e,f,g}   Stella, Philip J ^{a,b,c,d,e,f,g}   Carlson, Mark D ^{a,b,c,d,e,f,g}   Moore, Dennis F ^{a,b,c,d,e,f,g}   Zon, Robin T ^{a,b,c,d,e,f,g}   Levitt, Ralph ^{a,b,c,d,e,f,g}   Jaslowski, Anthony J ^{a,b,c,d,e,f,g}  

^a MAYO CLINIC ROCHESTER   (United States)

^b Michigan Cancer Research Consortium   (United States)

^c MISSOURI VALLEY CANCER CONSORTIUM   (United States)

^d WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

^e Northern Indiana Cancer Research Consortium   (United States)

^f MeritCare Hospital   (United States)

^g St Vincent Regional Cancer Center CCOP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PILOCARPINE; PLACEBO; MUSCARINIC AGENT;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; ATTITUDE TO HEALTH; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; RANDOMIZED CONTROLLED TRIAL; RIGOR; SIDE EFFECT; SWEATING; TREATMENT DURATION; TREATMENT REFUSAL; URINARY FREQUENCY; VAGINAL DRYNESS; WOMEN'S HEALTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; VAGINA DISEASE;

ADMINISTRATION, ORAL; ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; MUSCARINIC AGONISTS; PILOCARPINE; POSTMENOPAUSE; VAGINAL DISEASES;

EID: 79960124011     PISSN: 15446794     EISSN: 1879596X     Source Type: Journal    
DOI: 10.1016/j.suponc.2011.02.005     Document Type: Article

References (25)

1. Pastore L.M., Carter R.A., Hulka B.S., Wells E. Self-reported urogenital symptoms in postmenopausal women: Women's Health Initiative. Maturitas 2004, 49:292-303.
2. Dennerstein L., Dudley E.C., Hopper J.L., Guthrie J.R., Burger H.G. A prospective population-based study of menopausal symptoms. Obstet Gynecol 2000, 96:351-358.
3. Ganz P.A., Greendale G.A., Petersen L., Zibecchi L., Kahn B., Belin T.R. Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. J Natl Cancer Inst 2000, 92:1054-1064.
4. Knobf M.T. The menopausal symptom experience in young mid-life women with breast cancer. Cancer Nurs 2001, 24:201-210. quiz 10-11.
5. Leclair D.M., Anandarajah G. Effects of estrogen deprivation: vasomotor symptoms, urogenital atrophy, and psychobiologic effects. Menopause 2002, 4:27-39.
6. Shapiro C.L., Manola J., Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001, 19:3306-3311.
7. Loprinzi C.L., Abu-Ghazaleh S., Sloan J.A., vanHaelst-Pisani C., Hammer A.M., Rowland K.M., et al. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol 1997, 15:969-973.
8. Nachtigall L.E. Comparative study: replens versus local estrogen in menopausal women. Fertil Steril 1994, 61:178-180.
9. Bygdeman M., Swahn M.L. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 1996, 23:259-263.
10. Wiseman L.R., Faulds D. Oral pilocarpine: a review of its pharmacological properties and clinical potential in xerostomia. Drugs 1995, 49:143-155.
11. Wynn R.L. Oral pilocarpine (Salagen)-a recently approved salivary stimulant. Gen Dent 1996, 44:26. 9-30.
12. Vivino F.B., Al-Hashimi I., Khan Z., LeVeque F.G., Salisbury P.L., Tran-Johnson T.K., et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. Arch Intern Med 1999, 159:174-181. P92-01 Study Group.
13. Le Veque G., Hendrix S. Oral pilocarpine to treat vaginal xerosis associated with chemotherapy-induced amenorrhea in pre-menopausal women. J Clin Oncol 2004, 22(suppl):749.
14. Suckling J., Lethaby A., Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2003, CD001500.
15. Nachtigall L.E. Clinical trial of the estradiol vaginal ring in the U.S. Maturitas 1995, 22(Suppl):S43-S47.
16. Carranza-Lira S., Fragoso-Diaz N., MacGregor-Gooch A.L., Garduno-Hernandez M.P., Rios-Calderon K., Aparicio H. Vaginal dryness assessment in postmenopausal women using pH test strip. Maturitas 2003, 45:55-58.
17. Therneau T.M. How many stratification factors are "too many" to use in a randomization plan?. Control Clin Trials 1993, 14:98-108.
18. Schiff M. A rationale for the use of summary measurements for the assessment of the effects of rheumatoid arthritis therapies. Clin Ther 2003, 25:993-1001.
19. Sloan J.A., Dueck A. Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trials. J Biopharm Stat 2004, 14:73-96.
20. Fairclough D.L., Peterson H.F., Cella D., Bonomi P. Comparison of several model-based methods for analysing incomplete quality of life data in cancer clinical trials. Stat Med 1998, 17:781-796.
21. Pilocarpine Micromedex, Accessed October 22, 2009. http://www.thomsonhc.com/clinicalxpert/librarian/ND_T/cx/ND_PR/cx/CS/819746/DUPLICATIONSHIELDSYNC/4572D2/ND_PG/cx/ND_B/cx/ND_P/cx/ND_gotoHCS/cx/ND_HCSLink/cx/PFActionId/clinicalxpert.DisplayDrugDocumentSuppressUsageTracking?itemId=922947%26contentSetId=100%26selectedTopicId=adverseEffectsSection%26mainSelected=Pilocarpine%26hubMask=0.
22. Labrie F., Archer D., Bouchard C., Fortier M., Cusan L., Gomez J.L., et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause 2009, 16:907-922.
23. Labrie F., Archer D., Bouchard C., Fortier M., Cusan L., Gomez J.L., et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause 2009, 16:923-931.
24. Labrie F., Archer D., Bouchard C., Fortier M., Cusan L., Gomez J.L., et al. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration. Menopause 2009, 16:897-906.
25. Buster J.E. Transvaginal dehydroepiandrosterone: an unconventional proposal to deliver a mysterious androgen that has no receptor or target tissue using a strategy with a new name: hormone precursor replacement therapy (HPRT). Menopause 2009, 16:858-859.